Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
Researchers found that the drugs, called Hsp90 inhibitors, specifically target and inactivate a mechanism commonly used by prostate cancer cells to evade the effects of standard treatment.
The findings provide vital information about the role of Hsp90 in drug-resistant prostate cancers, and open up potential new routes to cancer treatment based on blocking this or related proteins.
A team at The Institute of Cancer Research, London, found that Hsp90 inhibitors countered the effect of malfunctions in the androgen receptor, which often occur in resistance to hormone treatments.
The research suggests that Hsp90 inhibitors could be effective in prostate cancers that have become resistant to treatment and started spreading round the body.
The study is published in the journal Cancer Research, and was mainly funded by the Wellcome Trust.
Hsp90 inhibitors are among several innovative new types of treatment designed to attack cancer indirectly, by destabilising multiple different proteins required for the growth and survival of cancer cells.
By destroying several cancer signals at once, they are designed to make it hard for cancers to escape the effects of treatment, giving them promise as potential 'resistance-busting' drugs.
The new research found that on top of their known effects on cancer, Hsp90 inhibition also blocked production of abnormal forms of the androgen receptor, stripping cancer cells of their defences against hormone treatments.
Prostate tumours rely on male hormones called androgens to grow and spread, and blocking androgen receptors can be an effective treatment.
However, cancer cells often generate abnormal forms of the androgen receptor that can be switched on all the time without the need for androgen hormone stimulation.
Researchers investigated the effect of Hsp90 inhibition on human cancer cells that produced the most common androgen receptor variant, called AR-V7. They grew the cancer cells in the lab and injected them into mice.
The researchers showed that Hsp90 inhibition reduced production of AR-V7 through a new and unexpected mechanism of action - by changing the way that messenger RNA molecules carrying the code for AR-V7 are processed.
Hsp90 inhibition also reduced the levels of the normal androgen receptor, and other important prostate cancer molecules called AKT and GR.
Study co-leader Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
"We call Hsp90 inhibitors 'network drugs' because they tackle several of the signals that are hijacked in cancer all at once, across a network rather than just a single signalling pathway. These drugs can hit cancer harder than those targeting only one protein, and look promising for preventing or overcoming drug resistance.
"Our study has found that Hsp90 inhibition can specifically stop resistance to hormone treatments in prostate cancer, through a completely new mechanism of action involving the processing of messenger RNA.
"It's an exciting discovery which adds a string to the bow of these cancer drugs, and means they could work against prostate cancers that have otherwise stopped responding to treatment."
Study co-leader Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, said:
"We have demonstrated for the first time that Hsp90 inhibitors can block the production of the most common abnormal androgen receptors that cause many prostate cancers to stop responding to current treatments.
"These drugs are already in clinical trials for several types of cancer, and I am excited that our work suggests they could also benefit men with prostate cancer who have otherwise run out of treatment options."
Notes to editors
For more information contact Claire Hastings on 020 7153 5380 or firstname.lastname@example.org. For enquiries out of hours, please call 07595 963 613.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today we are world leaders at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk